MAPT and Alzheimer disease: Network pharmacology analysis validated the multi-component and multi-target therapeutic mechanisms of KXS for treatment of AD, involving inhibiting Tau protein hyperphosphorylation, inflammation, and apoptosis (Jiao et al., 2022; Wang et al., 2023).